戀夜直播app官方正版下载_戀夜直播高品质美女在线视频互动社区_戀夜直播官方版

Bruker acquires Anasys and grows IR/thermal measurement portfolio

source:Laser Focus World

  release:Nick

keywords: Bruker infrared spectroscopy measurement instruments

Time:2018-04-23

Bruker (Billerica, MA) announced that it has acquired Anasys Instruments (Santa Barbara, CA), a privately held company that develops and manufactures nanoscale infrared spectroscopy and thermal measurement instruments. This acquisition adds to Bruker's portfolio of Raman and FTIR spectrometers, as well as to its nanoscale surface science instruments, such as atomic force microscopy and white-light interferometric 3D microscopy. Financial details of the transaction were not disclosed.

Anasys has pioneered the field of nanoprobe-based thermal and infrared measurements. Its nanoIR products are used by academic and industrial scientists and engineers in soft-matter and hard-matter materials science, and in life science applications. Recently Anasys introduced even higher performance with 10 nm resolution nanoIR imaging.

 

"We are very excited to add this strategic, high-growth area to our portfolio of nanoscale microscopy and spectroscopy measurement products," said Mark R. Munch, president of the Bruker NANO Group. "There are tremendous application and technology synergies that will benefit our customers."

"We are very happy to have found a company like Bruker to take the business to the next level," added Roshan Shetty, co-founder and former CEO of Anasys. "We feel that Bruker's history in innovative instrument research, and Bruker's global reach will build on our own history of unique and pioneering achievements in thermal and nanoIR measurements."

Anasys Instruments provides photothermal IR spectroscopy solutions from the nanoscale to the sub-micron and macro scales.

For more than 55 years, Bruker scientific instruments and high-value analytical and diagnostic solutions have enabled scientists to explore life and materials at molecular, cellular, and microscopic levels. Today, Bruker says it has become a provider of systems for cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology, and molecular pathology research.